Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.60 |
| ▸ | KIF11 | P52732 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | RGS12 | O14924 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | HRH1 | P35367 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4691627 | 1.00 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4690756 | 1.00 | SLC6A2 (0.60) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4689457 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4686469 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4686468 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4689826 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4686781 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4686779 | 0.87 | SLC6A2 (0.51) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4685912 | 0.83 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4KIF11LMNA | |
| SCHEMBL4685901 | 0.83 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4KIF11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318997-A1 | NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF | AMR TECHNOLOGY, INC. (US) | 2008-12-25 | — | — | US | claimed |
| US-7419985-B2 | 4-Phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-7084152-B2 | 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2006-08-01 | — | — | US | claimed |
| US-20060111385-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | ALBANY MOLECULAR RESEARCH, INC. | 2006-05-25 | — | — | US | claimed |
| US-20060111386-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2006-05-25 | — | — | US | claimed |
| US-20060025435-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | AMR TECHNOLOGY, INC. (US) | 2006-02-02 | — | — | US | claimed |
| US-20040248925-A1 | Use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence | PHARMACIA & UPJOHN COMPANY | 2004-12-09 | — | — | US | claimed |
| US-20020091134-A1 | Novel 4-phenyl substituted tetrahydroiso quinolines therapeutic use thereof | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2002-07-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111386-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | HTR2C, HTR3B, HTR2B | SLC6A2 10/4885SLC6A3 13/4885SLC6A4 19/4885 |
| US-20060111385-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | HTR2C, HTR3B, HTR2B | SLC6A2 10/4885SLC6A3 13/4885SLC6A4 19/4885 |
| US-20080318997-A1 | NOVEL 4-PHENYL SUBSTITUTED TETRAHYDROISOQUINOLINES AND THERAPEUTIC USE THEREOF | GRIN2C, HTR3B, HTR2C | SLC6A2 5/4885SLC6A3 9/4885SLC6A4 14/4885 |
| US-20020091134-A1 | Novel 4-phenyl substituted tetrahydroiso quinolines therapeutic use thereof | HTR3B, GRIN2C, HTR2B | SLC6A2 5/4885SLC6A3 7/4885SLC6A4 12/4885 |
| US-20060025435-A1 | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof | GRIN2C, HTR3B, HTR2C | SLC6A2 5/4885SLC6A3 9/4885SLC6A4 14/4885 |
| US-20040248925-A1 | Use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence | HTR3B, HTR2C, HTR2B | SLC6A2 56/4885SLC6A3 223/4885SLC6A4 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.